Literature DB >> 17022012

Impact of highly active antiretroviral therapy on outcome of cholecystectomy in patients with human immunodeficiency virus infection.

D Foschi1, P Cellerino, F Corsi, A Casali, A Rizzi, I Righi, E Trabucchi.   

Abstract

BACKGROUND: Highly active antiretroviral therapy (HAART) reduces virus proliferation and significantly decreases the rate of septic and opportunistic complications in patients infected with human immunodeficiency virus (HIV). Although surgery is performed routinely on patients receiving HAART, the effect of this treatment on surgical outcome has not been examined in detail.
METHODS: This retrospective study reviewed 54 consecutive patients with HIV infection who underwent surgical cholecystectomy: 31 patients were on HAART, 13 on nucleoside analogue reverse transcriptase inhibitors (NRTIs) and ten were receiving no specific therapy. Characteristics of HIV-1 infection, laboratory investigations, characteristics of the gallbladder disease, type of operation, postoperative course, morbidity and mortality were recorded. Univariable analysis and unconditional logistic regression were performed to determine factors related to postoperative complications and death.
RESULTS: The three groups were similar in terms of HIV-1 infection characteristics. In univariable analysis HAART and laparoscopic cholecystectomy were associated with a significantly lower complication rate, whereas only HAART was shown to be protective by logistic regression analysis. A low HIV RNA load and a high CD4(+) cell count were significant predictors of uncomplicated surgical outcomes.
CONCLUSION: HAART significantly reduces the risk of complications after cholecystectomy in patients with HIV infection or acquired immune deficiency syndrome.

Entities:  

Mesh:

Year:  2006        PMID: 17022012     DOI: 10.1002/bjs.5527

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

1.  CD4 Count is Still a Valid Indicator of Outcome in HIV-Infected Patients Undergoing Major Abdominal Surgery in the Era of Highly Active Antiretroviral Therapy.

Authors:  A Chichom-Mefire; M Azabji-Kenfack; J Atashili
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

2.  Thirty-day postoperative mortality among individuals with HIV infection receiving antiretroviral therapy and procedure-matched, uninfected comparators.

Authors:  Joseph T King; Melissa F Perkal; Ronnie A Rosenthal; Adam J Gordon; Stephen Crystal; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; David Rimland; Michael S Simberkoff; Amy C Justice
Journal:  JAMA Surg       Date:  2015-04       Impact factor: 14.766

3.  Perioperative Antiretroviral Regimen for HIV/AIDS Patients Who Underwent Abdominal Surgery.

Authors:  Jing Yang; Guo Wei; Yong He; Xin Hua; Shifeng Feng; Yong Zhao; Tingyu Chen; Hua Wang; Liang Guo
Journal:  World J Surg       Date:  2020-06       Impact factor: 3.282

4.  Anti-infective treatment in HIV-infected patients during perioperative period.

Authors:  Baochi Liu; Lei Zhang; Ruizhang Guo; Jinsong Su; Lei Li; Yanhui Si
Journal:  AIDS Res Ther       Date:  2012-11-27       Impact factor: 2.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.